Inherited metabolic disorders
Gaucher disease type 3
Also called: GD3 · GD III · type 3 Gaucher disease · Gaucher disease · Chronic neuronopathic Gaucher disease · Subacute neuronopathic Gaucher disease · Norrbottnian Gaucher disease
What a donor has to do with this
A transplant is not a standard part of treating this condition. It is used rarely, in particular situations, and most people diagnosed with it will not have one.
This is our reading of published transplant guidelines for this condition, not a measurement of how many people need a donor. Where a source actually counted donors, the figure and the people it counted are shown further down. Where none did, we say so rather than estimate.
This page is not written out in full yet
We have not written this condition out in full yet. What is on this page — how a donor fits in, who it affects, and the sources behind that — is researched and linked, but the plain-English explanation of the condition itself is still to come.
What the evidence says
- Who it affects
- Typical onset/diagnosis: chronic neuronopathic Gaucher disease begins in childhood; a UK/Sweden transplant cohort was diagnosed at 12–20 months (median 16 months). Evidence: UK/Sweden cohort (published 2022); the Norrbottnian form clusters in northern Sweden.
- Treatments other than a transplant
- Glucocerebrosidase enzyme replacement therapy — approved standard systemic therapy — multiple regions — Controls visceral, hematologic, and skeletal disease but has limited direct CNS penetration.
- If a transplant is used, the cells come from
- bone marrow: used in all 9 patients in the UK and Sweden cohort transplanted in 1980–1990 and published in 2022; mobilized peripheral blood stem cells: not reported in the opened cohort evidence; umbilical cord blood: not reported in the opened cohort evidence; dominance: bone marrow was the only graft source reported in the opened cohort
- How often the donor was unrelated
- Not reported. No source we could read states this for this condition, so we do not give a number. An estimate here would be a guess dressed as evidence.
Where this gets complicated
Modern enzyme replacement has made allogeneic HCT exceptional; historical long-term survivors are strongly selected and predate current supportive care.; Visceral correction does not guarantee arrest of horizontal gaze palsy, seizures, or other CNS manifestations.
“Although neurological disease progressed in this cohort of patients, there may be a future role for HSCT in the treatment of nGD.”
It describes what teams consider in general. It cannot say what applies to any one person. Read the source.
Registries need people
An unrelated donor is not a usual part of treating this condition. Registering still matters, for the many conditions where it is.
Joining a registry is a cheek swab and a short health form. You are not matched to a condition — you are matched to a person, and it could be someone with any of the conditions in this library. You are contacted only if you turn out to be a possible match for someone, and you can ask questions and decline before anything else happens.
Related conditions
Others in inherited metabolic disorders. They are genuinely different diseases with different treatments — the group name is not a diagnosis.
Where this came from
- Gaucher disease type III — NIH NCATS GARD, updated 2026-06
- EBMT Handbook, Chapter 91: Inborn Errors of Metabolism and Osteopetrosis — EBMT/Springer, 2024-04-11
- Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease — Orphanet Journal of Rare Diseases / Springer Nature, 2022